Literature DB >> 33864107

Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention.

Joseph H Yacoub1,2, David Mauro3, Andrew Moon3, Aiwu R He4, Mustafa R Bashir5,6, Christine C Hsu7, Thomas M Fishbein7, Lauren M B Burke8.   

Abstract

Locoregional therapies can be offered to hepatocellular carcinoma patients as a bridge to transplant, to downstage disease burden for transplant eligibility, or for disease control to prolong survival. Systemic therapies also play a large role in HCC treatment, occasionally in conjunction with other methods. This manuscript reviews the various treatment options for HCC with a historically noncurative intent.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Chemoembolization; Hepatocellular carcinoma; Locoregional therapies; Radioembolization; Stereotactic body radiotherapy; Systemic therapies

Mesh：

Year:  2021        PMID： 33864107     DOI： 10.1007/s00261-021-03074-z

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  55 in total

Review 1.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Authors:  J-L Raoul; B Sangro; A Forner; V Mazzaferro; F Piscaglia; L Bolondi; R Lencioni
Journal:  Cancer Treat Rev       Date:  2010-08-17       Impact factor: 12.111

2.  Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma.

Authors:  Aline Mähringer-Kunz; Roman Kloeckner; Michael B Pitton; Christoph Düber; Irene Schmidtmann; Peter R Galle; Sandra Koch; Arndt Weinmann
Journal:  Cardiovasc Intervent Radiol       Date:  2017-02-14       Impact factor: 2.740

Review 3.  Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel.

Authors:  Ann Lii Cheng; Deepak Amarapurkar; Yee Chao; Pei-Jer Chen; Jean-François Geschwind; Khean L Goh; Kwang-Hyub Han; Masatoshi Kudo; Han Chu Lee; Rheun-Chuan Lee; Laurentius A Lesmana; Ho Yeong Lim; Seung Woon Paik; Ronnie T Poon; Chee-Kiat Tan; Tawesak Tanwandee; Gaojun Teng; Joong-Won Park
Journal:  Liver Int       Date:  2013-11-20       Impact factor: 5.828

Review 4.  Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

Authors:  Laura Marelli; Rosa Stigliano; Christos Triantos; Marco Senzolo; Evangelos Cholongitas; Neil Davies; Jonathan Tibballs; Tim Meyer; David W Patch; Andrew K Burroughs
Journal:  Cardiovasc Intervent Radiol       Date:  2007 Jan-Feb       Impact factor: 2.740

5.  Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.

Authors:  Katerina Malagari; Mary Pomoni; Alexis Kelekis; Anastasia Pomoni; Spyros Dourakis; Themis Spyridopoulos; Hippokratis Moschouris; Emmanouil Emmanouil; Spyros Rizos; Dimitrios Kelekis
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-24       Impact factor: 2.740

Review 6.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

Review 7.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

8.  Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone.

Authors:  Karen T Brown; Richard K Do; Mithat Gonen; Anne M Covey; George I Getrajdman; Constantinos T Sofocleous; William R Jarnagin; Michael I D'Angelica; Peter J Allen; Joseph P Erinjeri; Lynn A Brody; Gerald P O'Neill; Kristian N Johnson; Alessandra R Garcia; Christopher Beattie; Binsheng Zhao; Stephen B Solomon; Lawrence H Schwartz; Ronald DeMatteo; Ghassan K Abou-Alfa
Journal:  J Clin Oncol       Date:  2016-02-01       Impact factor: 44.544

9.  Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Authors:  Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740

10.  Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma.

Authors:  R Golfieri; E Giampalma; M Renzulli; R Cioni; I Bargellini; C Bartolozzi; A D Breatta; G Gandini; R Nani; D Gasparini; A Cucchetti; L Bolondi; F Trevisani
Journal:  Br J Cancer       Date:  2014-06-17       Impact factor: 7.640
View more
  1 in total

Review 1.  Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations.

Authors:  Adam Hatzidakis; Lukas Müller; Miltiadis Krokidis; Roman Kloeckner
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.